PC786
/ Pulmocide
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 01, 2024
Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development.
(PubMed, Rev Med Virol)
- "Results from 59 studies were extracted, covering efficacy and safety data on six mAbs (motavizumab, motavizumab-YTE, nirsevimab, ALX-0171, suptavumab, clesrovimab) and 12 AV therapies (ALN-RSV01, RSV604, presatovir, MDT-637, lumicitabine, IFN-α1b, rilematovir, enzaplatovir, AK0529, sisunatovir, PC786, EDP-938). Moving forward, passive immunisation and treatment options for RSV infection will play a significant role in reducing the health burden of RSV, complementing recent advancements in vaccine development. TRIAL REGISTRATION: PROSPERO registration: CRD42022376633."
Journal • Review • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNA1
December 22, 2022
Immunity Cell Responses to RSV and the Role of Antiviral Inhibitors: A Systematic Review.
(PubMed, Infect Drug Resist)
- "EDP-938 inhibits viral nucleoprotein (N), while GRP-156784 blocks the activity of respiratory syncytial virus ribonucleic acid (RNA) polymerase. PC786 inhibits non-structural protein 1 (NS-1) gene, RANTES transcripts, virus-induced CCL5, IL-6, and mucin increase...Many respiratory syncytial virus inhibitors are proposed; however, only palivizumab and ribavirin are approved for prophylaxis and treatment, respectively. Hence, this review is focused on immunity cell responses to respiratory syncytial virus and the role of antiviral inhibitors."
Journal • Review • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • CCL11 • CCL3 • CD8 • CXCL10 • GZMA • IFNA1 • IFNB1 • IFNG • IL13 • IL1B • IL2 • IL4 • IL6 • TNFA
1 to 2
Of
2
Go to page
1